Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company has developed and commercialized a drug for the treatment of hepatitis B virus that it licensed to Novartis Pharma AG (Novartis). The Company also has developed through proof-of-concept clinical testing a drug candidate (IDX899) for the treatment of human immunodeficiency virus (HIV). In February 2009, the Company entered into a license agreement (GSK License Agreement) with GlaxoSmithKline (GSK) to develop, manufacture and commercialize its NNRTI compounds, including IDX899, for the treatment of human diseases, including HIV/AIDS, on a worldwide basis.